 |
| Compounding Chemotherapy Market |
Compounding chemotherapy refers to customized medication formulation prepared by pharmacists for specific patients. Compounding pharmacists create customized medications from commercially available ingredients including chemotherapy drugs as per physician's prescription. Compounding chemotherapy drugs are customized as per specific ailments, dosage requirements, administration route preferences of patients to maximize therapeutic effects and minimize toxic effects. The global cancer burden continues to rise with an estimated 19.3 million new cases and 10 million cancer deaths in 2022. The rising prevalence of various forms of cancer like lung cancer, breast cancer, prostate cancer and others are anticipated to increase the demand for tailored chemotherapy.
The Global Compounding Chemotherapy Market is estimated to be valued at US$ 11.76 Mn in 2024 and is expected to exhibit a CAGR of 2.8% over the forecast period 2024 To 2031.
Key Takeaways
Key players operating in the Compounding Chemotherapy are Singapore Airlines,Air New Zealand,Qantas,Qatar Airways,Virgin Australia,Emirates,All Nippon Airways,EVA Air,American Airline,Spicejet,The Boeing Company,Airbus SE,Lockheed Martin Corporation,Textron Inc,Embraer S.A. Compounding chemotherapy provides opportunities for customized treatment for patients with special needs like pediatric patients, geriatric patients and patients with pre-existing conditions requiring dosage adjustments. The advancements in API sourcing and compounding techniques allows opportunities for pharmaceutical companies to expand globally and provide customized Compounding Chemotherapy Market Size for cancer patients in different geographies.
The key players are focusing on strategic collaborations and partnerships to expand globally and cater to increasing demand for customized chemotherapy. For instance, in 2022, Qatar Airways collaborated with American Airlines to increase connectivity and provide seamless travel experience. Similarly, Emirates partnered with JetBlue to codeshare and provide one-stop flight options between the Middle East and North America.
North America dominates the global compounding chemotherapy market due to high cancer prevalence, availability of advanced healthcare facilities and favorable reimbursement policies for customized treatments. However, the Asia Pacific region provides lucrative opportunities for market expansion owing to rising healthcare expenditure, growing medical tourism and increasing focus on personalized medicine in countries like China, India and Japan. The key players are focusing on expanding through partnerships, acquisitions and by establishing manufacturing & distribution centers in high growth regions.
Market drivers:
- Increasing cancer prevalence worldwide: As per WHO, cancer burden is estimated to rise by ~60% in next two decades. This growing cancer population widens the market for compounding chemotherapy drugs.
- Personalized medicine and customized treatment demand: Compounding chemotherapy enables customized treatment as per the unique requirement of each patient in terms of dose, route of administration, etc amplifying its demand.
Market restraints:
- Stringent regulations: Compounded drugs are faced with stringent regulations pertaining to preparation standards, stability testing requirements etc adding compliance complexities restricting market growth.
- High infrastructure and compounding costs: Setting up of compounding facilities involves high capital investments impacting commercialization of compounded drugs. The complex formulation process also adds to per unit drug costs limiting market revenues.
Segment Analysis
The compounded chemotherapy market can be segmented into drugs/product and end user. Anthracyclines, Taxanes, Antimetabolites are the dominating drug sub-segments as these are widely used and effective in treating various types cancers. Among end users, hospitals dominated the market as majority of chemotherapy is conducted in hospitals setting due to requirement of close medical monitoring, treatment and management of side effects.
Global Analysis
North America region dominates the compounded chemotherapy market owing to increasing incidence of cancer, rising demand for advanced treatments and well developed healthcare infrastructure. Asia Pacific is expected to witness fastest growth during the forecast period owing to increasing patient pool, rising medical tourism, growing healthcare spending in countries like China, India. Europe holds significant share due to availability of advanced treatment options, presence of key market players and increasing research activities for development of novel drugs. Latin America and Middle East & Africa are expected exhibit moderate growth during the forecast period.
Get more insights on Compounding Chemotherapy Market
About Author:
Money Singh is a seasoned content writer with over four years of experience in the market research sector. Her expertise spans various industries, including food and beverages, biotechnology, chemical and materials, defense and aerospace, consumer goods, etc. (https://www.linkedin.com/in/money-singh-590844163)
Comments
Post a Comment